Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2

Current Women's Health Reports

Volumn 3, Issue 1, 2003, Pages 27-32

  Swisher, Elizabeth ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; DNA; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; TAXANE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; DNA SEQUENCE; DRUG SENSITIVITY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; MUTATIONAL ANALYSIS; OVARIECTOMY; OVARY CANCER; REVIEW; SALPINGOOOPHORECTOMY; TRANSCRIPTION REGULATION; TRANSVAGINAL ECHOGRAPHY; GENETIC PREDISPOSITION; GENETICS; MORTALITY; MUTATION; OVARY TUMOR; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 0037567703     PISSN: 15345874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
3. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE: Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002, 94:61-67.
4. Wilson CA, Ramos L, Villasenor MR, et al.: Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999, 21:236-240.
5. Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408.
6. Ford D, Easton DF, Bishop DT, et al.: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994, 343:692-695.
7. Whittemore AS, Gong G, Itnyre J: Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997, 60:496-504.
8. Risch HA, McLaughlin JR, Cole DE, et al.: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001, 68:700-710.
9. Bandera CA, Muto MG, Schorge JO, et al.: BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998, 92(4 Pt 1):596-600.
10. Aziz S, Kuperstein G, Rosen B, et al.: A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001, 80:341-345.
11. Paley PJ, Swisher EM, Garcia RL, et al.: Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001, 80:176-180.
12. Cancer risks in BRCA2 mutation carriers.The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999, 91:1310-1316.
13. Lancaster JM, Carney ME, Gray J, et al.: BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1. Br J Cancer 1998, 78:1417-1420.
14. Liede A, Cohen B, Black DM, et al.: Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer 2000, 82:705-711.
15. Peelen T, van Vliet M, Petrij-Bosch A, et al.: A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997, 60:1041-1049.
16. Liede A, Malik IA, Aziz Z, et al.: Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 2002, 71:595-606.
17. Khoo US, Chan KY, Cheung AN, et al.: Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat 2002, 19:307-308.
18. Tonin PN, Mes-Masson AM, Futreal PA, et al.: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998, 63:1341-1351.
19. Kauff ND, Perez-Segura P, Robson ME, et al.: Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 2002, 39:611-614.
20. Moslehi R, Chu W, Karlan B, et al.: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000, 66:1259-1272.
21. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995, 57:1457-1462.
22. Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996, 14:185-187.
23. Abeliovich D, Kaduri L, Lerer I, et al.: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997, 60:505-514.
24. Beller U, Halle D, Catane R, et al.: High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 1997, 67:123-126.
25. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
26. Stratton JF, Gayther SA, Russell P, et al.: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997, 336:1125-1130.
27. Gayther SA, Mangion J, Russell P, et al.: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997, 15:103-105.
28. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al.: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999, 180:917-928.
29. Burke W, Daly M, Garber J, et al.: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997, 277:997-1003.
30. van Nagell JR, Jr, DePriest PD, Reedy MB, et al.: The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000, 77:350-356.
31. Lerman C, Hughes C, Croyle RT, et al.: Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000, 31:75-80.
32. Narod SA, Sun P, Ghadirian P, et al.: Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001, 357:1467-1470.
33. Modan B, Hartge P, Hirsh-Yechezkel G, et al.: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:235-240.
34. Narod SA, Risch H, Moslehi R, et al.: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998, 339:424-428.
35. Ursin G, Henderson BE, Haile RW, et al.: Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997, 57:3678-3681.
36. Grabrick DM, Hartmann LC, Cerhan JR, et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000, 284:1791-1798.
37. Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609-1615.
38. Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.
39. Meiser B, Tiller K, Gleeson MA, et al.: Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology 2000, 9:496-503.
40. Tiller K, Meiser B, Butow P, et al.: Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol Oncol 2002, 86:212-219.
41. Swisher EM, Babb S, Whelan A, et al.: Prophylactic oophorectomy and ovarian cancer surveillance: patient perceptions and satisfaction. J Reprod Med 2001, 46:87-94.
42. Leeper K, Garcia R, Swisher E, et al.: Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002, 87:52-56.
43. Lu KH, Garber JE, Cramer DW, et al.: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000, 18:2728-2732.
44. Colgan TJ, Murphy J, Cole DE, et al.: Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001, 25:1283-1289.
45. Agoff SN, Mendelin JE, Grieco VS, Garcia RL: Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002, 26:171-178.
46. Boyd J, Sonoda Y, Federici MG, et al.: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000, 283:2260-2265.
47. Rubin SC, Benjamin I, Behbakht K, et al.: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996, 335:1413-1416.
48. Werness BA, Ramus SJ, Whittemore AS, et al.: Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000, 31:1420-1424.
49. Ramus SJ, Bobrow LG, Pharoah PD, et al.: Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999, 25:91-96.
50. Pharoah PD, Easton DF, Stockton DL, et al.: Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 1999, 59:868-871.
51. Loman N, Johannsson O, Bendahl PO, et al.: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998, 83:310-319.
52. Verhoog LC, Brekelmans CT, Seynaeve C, et al.: Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999, 17:3396-3402.
53. Brunet JS, Narod SA, Tonin P, Foulkes WD: BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 1997, 336:1256; discussion 1256-1257.
54. Modan B: BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 1997, 336:1255; discussion 1256-1257.
55. McGuire V, Whittemore AS, Norris R, Oakley-Girvan I: Survival in epithelial ovarian cancer patients with prior breast cancer. Am J Epidemiol 2000, 152:528-532.
56. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al.: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002, 20:463-466.
57. Aida H, Takakuwa K, Nagata H, et al.: Clinical features of ovarian cancer in Japanese women with germline mutations of BRCA1. Clin Cancer Res 1998, 4:235-240.
58. Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998, 16:397-404.
59. Ansquer Y, Gautier C, Fourquet A, et al.: Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 1998, 352:541.
60. Verhoog LC, Brekelmans CT, Seynaeve C, et al.: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998, 351:316-321.
61. Abbott DW, Freeman ML, Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998, 90:978-985.
62. Ichikawa Y, Lemon SJ, Wang S, et al.: Microsatellite instability and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in hereditary nonpolyposis colorectal cancer family members. Cancer Genet Cytogenet 1999, 112:2-8.
63. Bhattacharyya A, Ear US, Koller BH, et al.: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000, 275:23899-23903.
64. Husain A, He G, Venkatraman ES, Spriggs DR: BRCA1 upregulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998, 58:1120-1123.
65. Lafarge S, Sylvain V, Ferrara M, Bignon YJ: Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001, 20:6597-6606.
66. Mullan PB, Quinn JE, Gilmore PM, et al.: BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001, 20:6123-6131.
67. Greenblatt MS, Chappuis PO, Bond JP, et al.: TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germline mutations: distinctive spectrum and structural distribution. Cancer Res 2001, 61:4092-4097.
68. Buller RE, Lallas TA, Shahin MS, et al.: The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res 2001, 7:831-838.
69. Rhei E, Bogomolniy F, Federici MG, et al.: Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 1998, 58:3193-3196.
70. Werness BA, Parvatiyar P, Ramus SJ, et al.: Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst 2000, 92:1088-1091.
71. Schuyer M, Berns EM: Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol Cell Endocrinol 1999, 155:143-152.